HHealthcare Read More How Lundbeck’s CEO aims to keep firm ‘punching above its weight’August 22, 2026 Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove…
HHealth Read More ASX healthcare stocks focusing on mitochondrial healthAugust 12, 2026 Known as the ‘powerhouse of the cell’, mitochondria are becoming a focus of research into ageing, health and…
EEconomy Read More China overtakes US to lead global R&D spending, hitting $615bnAugust 8, 2026 Science Corporate, university expenditures for 2024 include computers, electronics China’s jump in R&D spending was driven by corporate…
EEconomy Read More China acknowledges ‘temperature gap’ between tech boom and traditional slumpAugust 3, 2026 A top theoretical journal of the Communist Party has acknowledged that a stark economic divide exists between China’s…
BBusiness Read More China’s rare earth industry has critical weakness, researchers warnJuly 5, 2026 China’s dominance in rare earth mining, refining and exports has long been viewed as a strategic advantage.But a…
AAustralia Read More Medical technology sector raises fresh concerns with Labor’s capital gains tax overhaul June 6, 2026 Cutting-edge medical technology companies say new restrictions on tax refunds for research and development will hurt health startups…
AAustralia Read More The Denholm R&D report, Ambitious Australia, wants to fix something that isn’t brokenApril 14, 2026 The ‘Ambitious Australia’ strategic review of Australian R&D from Tesla’s Robyn Denholm is aptly named, but it’s arguably…
EEconomy Read More Does China’s science budget boost confirm it is listening to everything Elon Musk says?March 5, 2026 With Beijing allocating 426.42 billion yuan (US$61.7 billion) for the sector, it is positioning frontiers such as future…
MMental health Read More Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals – Endpoints NewsFebruary 18, 2026 Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsCompass Pathways stock soars after…
MMedication Read More Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial – Endpoints NewsFebruary 10, 2026 Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial Endpoints NewsRO: Fenebrutinib matched ocrelizumab in slowing PPMS progression,…
EEconomy Read More Open Questions | Lawrence Lau on why China must ‘work smarter’ and how it can invent from scratchFebruary 2, 2026 Lawrence J. Lau is a Hong Kong economist specialising in economic development and East Asian economies. He was…
HHealthcare Read More Women lose 75 million years of healthy life annually – yet receive only 6% of health fundingJanuary 26, 2026 Women and girls make up 49 percent of the global population, and while they live longer than men,…